Analysts expect Inovalon Holdings Inc (NASDAQ:INOV) to announce earnings per share of $0.12 for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Inovalon’s earnings. The highest EPS estimate is $0.14 and the lowest is $0.11. Inovalon posted earnings per share of $0.09 in the same quarter last year, which would suggest a positive year-over-year growth rate of 33.3%. The business is expected to issue its next quarterly earnings report on Wednesday, November 7th.
On average, analysts expect that Inovalon will report full-year earnings of $0.35 per share for the current year, with EPS estimates ranging from $0.32 to $0.39. For the next year, analysts forecast that the business will post earnings of $0.43 per share, with EPS estimates ranging from $0.32 to $0.54. Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Inovalon.
Inovalon (NASDAQ:INOV) last released its earnings results on Wednesday, August 1st. The technology company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.08. The company had revenue of $152.80 million for the quarter, compared to analysts’ expectations of $147.09 million. Inovalon had a negative net margin of 0.40% and a positive return on equity of 3.69%. Inovalon’s revenue for the quarter was up 38.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.08 EPS.
INOV has been the topic of several research analyst reports. BidaskClub upgraded shares of Inovalon from a “hold” rating to a “buy” rating in a research note on Saturday, July 7th. Zacks Investment Research upgraded shares of Inovalon from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 11th. Finally, ValuEngine upgraded shares of Inovalon from a “sell” rating to a “hold” rating in a research note on Thursday, August 2nd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $12.67.
INOV stock traded down $0.03 during mid-day trading on Wednesday, hitting $10.16. The company had a trading volume of 13,777 shares, compared to its average volume of 545,527. The stock has a market cap of $1.53 billion, a P/E ratio of 44.61, a PEG ratio of 2.55 and a beta of 1.11. Inovalon has a 12-month low of $8.90 and a 12-month high of $17.70. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 1.38.
A number of hedge funds have recently made changes to their positions in the business. FMR LLC lifted its stake in Inovalon by 372.5% in the 2nd quarter. FMR LLC now owns 4,770,907 shares of the technology company’s stock worth $47,351,000 after purchasing an additional 3,761,107 shares in the last quarter. BlackRock Inc. lifted its stake in Inovalon by 12.0% in the 2nd quarter. BlackRock Inc. now owns 4,717,964 shares of the technology company’s stock worth $46,824,000 after purchasing an additional 505,301 shares in the last quarter. Summit Partners L P purchased a new stake in Inovalon in the 2nd quarter worth $34,631,000. Tikvah Management LLC lifted its stake in Inovalon by 97.2% in the 1st quarter. Tikvah Management LLC now owns 1,963,400 shares of the technology company’s stock worth $20,812,000 after purchasing an additional 968,000 shares in the last quarter. Finally, Senvest Management LLC lifted its stake in Inovalon by 22.6% in the 1st quarter. Senvest Management LLC now owns 1,274,700 shares of the technology company’s stock worth $13,512,000 after purchasing an additional 235,000 shares in the last quarter. Institutional investors and hedge funds own 33.99% of the company’s stock.
Inovalon Holdings, Inc, a technology company, provides cloud-based platforms empowering a data-driven transformation from volume-based to value-based models in the healthcare industry. The company's platform enables the assessment and enhancement of clinical and quality outcomes and financial performance.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovalon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalon and related companies with MarketBeat.com's FREE daily email newsletter.